Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial

Predictive role of the overexpression for CXCR4, C-Met, and VEGF-C among breast cancer patients: A meta-analysis

(2016) Fang Wang et al.   BREAST

Prognostic Significance of High VEGF-C Expression for Patients with Breast Cancer: An Update Meta Analysis

(2016) Zhiqiao Zhang et al.   PLoS One

Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer

(2016) Domenico Ribatti et al.   Translational Oncology

Clinical implications of the intrinsic molecular subtypes of breast cancer

(2015) Aleix Prat et al.   BREAST

Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression

(2015) M. C. U. Cheang et al.   ONCOLOGIST

Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy

(2015) Lamis Yehia et al.   PLoS One

A novel model for Ki67 assessment in breast cancer

(2014) Quinci Romero et al.   Diagnostic Pathology

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel

(2012) George Fountzilas et al.   PLoS One

Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial

(2011) Helen Gogas et al.   BREAST CANCER RESEARCH AND TREATMENT

The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses’ Health Study

(2011) Ying Liu et al.   BREAST CANCER RESEARCH AND TREATMENT

Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study

(2010) Shaheenah Dawood et al.   BREAST CANCER RESEARCH AND TREATMENT

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

(2010) Lisa Rydén et al.   BREAST CANCER RESEARCH AND TREATMENT

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer

(2009) B. K. Linderholm et al.   ANNALS OF ONCOLOGY

Lymphangiogenic Characteristics of Triple Negativity in Node-Negative Breast Cancer

(2009) Huan-Tao Liu et al.   INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY

Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer

(2008) Xiao-Hua Zhang et al.   BMC CANCER

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE